MedTrace Logo

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

NCT00483041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2014-03-07

Study results available
· View outcomes & findings →

Summary

To evaluate the effect of MEDI-528 in adults with atopic asthma.

Conditions

Interventions

OTHER

PLACEBO

Placebo administered as a single intravenous infusion

BIOLOGICAL

MEDI528 9 mg/kg

MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Joseph Parker, M.D. · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-10-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483041 on ClinicalTrials.gov